US FDA: Seeks Diverse Experts for Advisory Committee Nominations

• The FDA has launched a nationwide recruitment effort to expand the expertise and perspectives on its advisory committees.
• Two Federal Register notices are being published to solicit scientific, technical, and professional voting members, as well as consumer representatives.
• Advisory committees provide independent recommendations on drugs, vaccines, medical devices, and other regulated products, informing critical public health decisions.
• Candidates for scientific roles need subject-matter expertise, while consumer representatives require advocacy experience and the ability to analyze technical data from a public perspective.
• The application portal is open, with deadlines for first consideration set for November 15, 2026, for consumer representatives and November 30, 2026, for scientific experts.

To ensure first consideration for these immediate openings, nominations for consumer representative positions must be submitted no later than November 15, 2026, while nominations for scientific, technical, professional, and other voting-member positions have an FDA advisory committee recruitment deadline of November 30, 2026.

The U.S. Food and Drug Administration has initiated a comprehensive, nationwide recruitment drive aimed at enriching the diversity of qualified voices and perspectives contributing to its advisory committees. These independent bodies play a pivotal role in shaping some of the most significant public health decisions in the United States. To facilitate this expansion, the agency is issuing two distinct Federal Register notices: one specifically targeting scientific, technical, and professional voting members to fill current or anticipated FDA scientific expert vacancies across all committees, and another dedicated to recruiting consumer representatives to ensure the public's voice is adequately represented in these crucial discussions.

Acting FDA Commissioner of Food and Drugs, Kyle Diamantas, J.D., underscored the importance of these panels, noting that FDA advisory committees convene leading scientific minds to tackle the most challenging questions in public health. He emphasized an active invitation to individuals from across the nation who are at the forefront of their respective fields, including clinicians, researchers, and community advocates. These individuals are sought to contribute the latest scientific insights, real-world experiences, and fresh perspectives to the FDA's deliberations, thereby strengthening the agency's decision-making process.

Advisory committees serve as a cornerstone of the FDA's regulatory framework, providing independent expertise and rigorous scrutiny as the agency navigates complex and rapidly evolving scientific landscapes. The Trump Administration has expressed a deep commitment to fortifying the collaborative relationship between the FDA and the nation's brightest minds, recognizing these committees as essential to a science-based and transparent regulatory process. These panels bring together a diverse array of scientific experts, such as physicians, researchers, and biostatisticians, alongside patient advocates and consumer representatives.

Their primary function involves evaluating evidence pertaining to drugs, vaccines, biologics, medical devices, and various other products regulated by the FDA. Through this meticulous review, they offer independent recommendations that are instrumental in assisting the FDA to make well-informed decisions that ultimately benefit the American public. The FDA, an agency within the U.S. Department of Health and Human Services, is tasked with safeguarding public health by ensuring the safety, effectiveness, and security of a wide range of products, including human and veterinary drugs, vaccines, biological products, and medical devices, in addition to overseeing the safety of the nation's food supply, cosmetics, and dietary supplements.

The FDA is actively seeking qualified candidates for FDA scientific expert vacancies spanning numerous scientific domains, including but not limited to oncology, cardiovascular medicine, neurology, genetics, and medical devices. Prospective applicants, whether aiming for scientific expert roles or FDA consumer representative positions, are encouraged to initiate their application through the centralized FDA Advisory Committee Membership Nomination application portal. Self-nominations are fully accepted, and successful candidates are invited to serve terms of up to four years.

For those seeking scientific and technical voting member positions, nominees must demonstrate pertinent subject-matter expertise relevant to one or more FDA advisory committees. They must also possess the ability to interpret complex scientific and technical information, exhibit an understanding of the public health significance of issues before the committee, and demonstrate the capacity to provide objective, independent advice. Nominees for consumer representative positions should showcase an affiliation with or active participation in consumer or community-based organizations, coupled with the ability to analyze technical data, discuss benefits and risks, and evaluate product safety and efficacy from a public perspective. The FDA will continuously accept nominations, considering them for both current and anticipated near-term vacancies. To ensure first consideration for these immediate openings, nominations for consumer representative positions must be submitted no later than November 15, 2026, while nominations for scientific, technical, professional, and other voting-member positions have an FDA advisory committee recruitment deadline of November 30, 2026. Submissions received after these specified dates will be held for consideration as subsequent vacancies arise.

Lawyers representing scientific experts, researchers, or consumer advocacy groups should advise clients on the opportunity to apply for FDA advisory committee positions, noting the specific application deadlines for first consideration. This allows clients to directly influence critical public health decisions and gain insight into FDA regulatory processes.

Source: Original reporting via FDA press release